Haleon (LON:HLN) Price Target Raised to GBX 390

Haleon (LON:HLN) had its price target boosted by Royal Bank Of Canada from GBX 370 to GBX 390 in a research note released on Tuesday,Digital Look reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Jefferies Financial Group restated a “buy” rating and issued a GBX 400 price objective on shares of Haleon in a report on Friday, July 31st. JPMorgan Chase & Co. dropped their target price on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a report on Thursday, June 25th. Deutsche Bank Aktiengesellschaft raised their price target on Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a research note on Friday, July 31st. Finally, Berenberg Bank lifted their price target on Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of GBX 399.

Haleon Stock Performance

Shares of Haleon stock opened at GBX 357.88 on Tuesday. Haleon has a one year low of GBX 317.80 and a one year high of GBX 416.10. The company has a market cap of £31.52 billion, a PE ratio of 19.77, a P/E/G ratio of 1.49 and a beta of 0.24. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The business has a 50-day simple moving average of GBX 355.13 and a 200-day simple moving average of GBX 362.74.

Haleon (LON:HLN) last issued its earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. On average, equities research analysts forecast that Haleon will post 19.5033282 EPS for the current fiscal year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.